GSK Prepares For Malaria Vaccine Roll-Out In Africa By 2015
This article was originally published in The Pink Sheet Daily
“While we have seen some decline in vaccine efficacy over time, the sheer number of children affected by malaria means that the number of cases of the disease the vaccine can help prevent is impressive,” GSK CEO Witty says.
You may also be interested in...
GSK’s malaria vaccine candidate is lead candidate in effort to solve the cold-chain storage problem.
Robust growth is expected in the global vaccines market driven by new players and products, improved coverage and distribution in both developed and emerging markets, and higher prices for new vaccines, an IMS consultant said during a New York Pharma Forum presentation.
Initiative to build health care infrastructure and create a sales channel for GSK medicines is starting to yield tangible results.